Loading Shukra Pharmaceuticals…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 24 | 6 | 39 | 6 | 5 |
| Operating profit | 18 | -0 | 26 | -1 | 1 |
| Operating margin | 76.8% | -4.9% | 67.2% | -20.9% | 9.9% |
| Net profit | 13 | -2 | 20 | 2 | 1 |
| Net margin | 55.1% | -27.1% | 52.0% | 40.5% | 19.1% |
| EPS (₹) | 0.30 | -0.04 | 0.47 | 0.05 | 0.02 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 57 | 33 | 75 | 59 |
| Operating profit | 25 | 10 | 17 | 4 |
| Operating margin | 44.6% | 29.8% | 23.3% | 6.0% |
| Net profit | 22 | 10 | 19 | 4 |
| Net margin | 38.9% | 29.4% | 24.9% | 7.5% |
| EPS (₹) | 0.50 | 0.22 | 0.42 | 0.14 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 117 | 87 | 78 | 75 |
| Total liabilities | 28 | 24 | 20 | 50 |
| Shareholders’ equity | 90 | 63 | 58 | 25 |
| Total debt | 5 | 4 | 3 | 5 |
| Cash & equivalents | 6 | 12 | 10 | 4 |
| Debt / equity | 0.06 | 0.07 | 0.05 | 0.20 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 4 | 8 | -5 | 3 |
| Capital expenditure | -16 | -3 | -2 | -4 |
| Free cash flow | -12 | 5 | -7 | -1 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 24.6% | 15.2% | 32.2% | 17.4% |
| Return on assets | 18.8% | 11.0% | 23.8% | 5.9% |
| Net margin | 38.9% | 29.4% | 24.9% | 7.5% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for SHUKRAPHAR. Finnhub coverage is limited for some India-listed stocks.